Avalyn Finishes Enrollment for Phase 2b MIST Trial of AP01 in Pulmonary Fibrosis
AVLN is trading near its 52-week low of $24.15 (14% above the low).
Summary
Avalyn Pharma has completed target enrollment of 375 patients in its Phase 2b MIST clinical trial for AP01, an inhaled therapy for progressive pulmonary fibrosis. This is a significant de-risking event for the clinical-stage biopharma, which recently completed an IPO to fund its pipeline. The milestone indicates the trial is progressing as planned towards a data readout. Topline 12-month clinical results are anticipated in the second half of 2027.
At the time of this announcement, AVLN was trading at $27.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $24.15 to $32.23. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.